Discovery - University of Dundee - Online Publications

Library & Learning Centre

Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16

Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16

Research output: Contribution to journalArticle

View graph of relations

Authors

  • K. M. Spaunhurst
  • A. M. Hogendorf
  • F. J. D. Smith
  • B. Lingala
  • M. E. Schwartz
  • A. Cywinska-Bernas
  • K. J. Zeman
  • J. Y. Tang

Research units

Info

Original languageEnglish
Pages875-878
Number of pages4
JournalBritish Journal of Dermatology
Journal publication date2012
Volume166
Issue4
DOIs
StatePublished

Abstract

Background Pachyonychia congenita (PC) is an autosomal dominant, very rare keratin disorder caused by mutations in any of at least four genes (KRT6A, KRT6B, KRT16 or KRT17), which can lead to hypertrophic nail dystrophy and palmoplantar keratoderma, among other manifestations. Classically, patients with mutations in KRT6A and KRT16 have been grouped to the PC-1 subtype (Jadassohn-Lewandowsky type) and KRT6B and KRT17 to PC-2 (Jackson-Lawler type). Objectives To describe clinical heterogeneity among patients with PC who have genetic mutations in KRT6A and KRT16.

Methods In 2004, the Pachyonychia Congenita Project established the International PC Research Registry (IPCRR) for patients with PC. All patients reporting here underwent genetic testing and responded to a standardized, validated survey about their PC symptoms. We report results from 89 patients with KRT6A mutations and 68 patients with KRT16 mutations.

Results Patients with PC who have KRT6A and KRT16 mutations display distinct phenotypic differences. Patients with PC-K6a experience earlier onset, more extensive nail disease anal more substantial disease outside palms and soles, as they reported a higher prevalence of oral leucokeratosis (P < 0.001), cysts (P < 0.001) and follicular hyperkeratosis (P < 0.001) compared with their PC-K16 counterparts.

Conclusion Phenotypic differences between patients with KRT6A and KRT16 mutations support adoption of a new classification system based on the mutant gene (PC-6a, PC-16) rather than the PC I nomenclature.

Documents

Library & Learning Centre

Contact | Accessibility | Policy